Split-course hypofractionated radiotherapy for aged and frail patients with head and neck cancers. A retrospective study of 75 cases.
Adenocarcinoma
/ mortality
Aged
Aged, 80 and over
Carcinoma, Squamous Cell
/ mortality
Female
Frail Elderly
Head and Neck Neoplasms
/ mortality
Humans
Male
Middle Aged
Organs at Risk
/ radiation effects
Progression-Free Survival
Radiation Dose Hypofractionation
Radiotherapy, Intensity-Modulated
/ adverse effects
Response Evaluation Criteria in Solid Tumors
Retrospective Studies
Cancer de la tête et du cou
Elderly
Head and neck cancer
IMRT
Personnes âgées
RCMI
Split course
Journal
Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique
ISSN: 1769-6658
Titre abrégé: Cancer Radiother
Pays: France
ID NLM: 9711272
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
07
03
2020
revised:
16
03
2020
accepted:
23
03
2020
pubmed:
5
11
2020
medline:
15
12
2020
entrez:
4
11
2020
Statut:
ppublish
Résumé
To assess the efficacy and the tolerance of a split course hypofractionated (SCH) radiotherapy (RT) protocol in head and neck cancer (HNC) for eldery and/or unfit patients (pts). Pts with HNC treated by SCH-RT in two institutions were included retrospectively. The main SCH RT regimen was two courses of 30 grays (Gy)/10 fractions separated by 2-4 weeks, without any systemic therapy. Between February 2012 and January 2019, 75 consecutive patients were analyzed. The median age was 80 years (range: 45.7-98.2) and 53 (70.7%) were men. Sixty-one (81.3%) pts had stage III/IV disease and 54 (72%) had at least two comorbidities. All of them were treated with intensity-modulated radiotherapy. Median follow-up was 10.6 months (range: 3.1-58.3). Local control at 12 and 24 months was 72.8% IC95%[62-85.5] and 51.7% IC95%[38.1-70.1] respectively. Progression free survival (PFS) at 12 and 24 months were 47.7% IC95%[37.4-60.8] and 41% IC95%[15-36.4] respectively, with a median of 11.5 months IC95%[8.9-17]. OS at 12 and 24 months were 60.4% IC95%[50-73.1] and 41% IC95%[30.6-54.9] respectively, with a median of 19.3 months IC95%[11.9-25.8]. Acute and late grade 3 or higher toxicities occurred for 6 (8%) and 3 (4%) pts. The present SCH-RT regimen seems effective, well-tolerated and could represent an alternative to palliative strategies for pts deemed unfit for standard exclusive RT.
Identifiants
pubmed: 33144061
pii: S1278-3218(20)30291-2
doi: 10.1016/j.canrad.2020.03.013
pii:
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
812-819Informations de copyright
Copyright © 2020 Société française de radiothérapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.